Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG505 SOSIP 664 gp140 vaccine adjuvanted - GSK/International AIDS Vaccine Initiative

Next Previous
Drug Profile

BG505 SOSIP 664 gp140 vaccine adjuvanted - GSK/International AIDS Vaccine Initiative

Alternative Names: BG505 SOSIP 664 gp140 adjuvanted vaccine; BG505 SOSIP.664 gp140 adjuvanted; BG505 SOSIP.664 gp140 Vaccine

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator International AIDS Vaccine Initiative
  • Developer GSK; International AIDS Vaccine Initiative; Weill Cornell Medical College
  • Class Immunotherapies; Protein vaccines; Recombinant proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 28 Dec 2023 BG 505 SOSIP 664 gp140 adjuvanted vaccine is still in phase I trial for HIV-infections (Prevention) in USA (IM) (NCT03699241)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in HIV-infections(Prevention) in Netherlands (IM)
  • 09 Aug 2023 International AIDS Vaccine Initiative plans a phase I trial for HIV infections (Prevention) in Netherlands (IM) (NCT05983874)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top